ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-OR090

Risk Factors for Infection in Patients with Glomerular Disease: An Analysis of the Cure Glomerulonephropathy (CureGN) Study

Session Information

  • Lupus and Then Some
    November 08, 2019 | Location: Ballroom C, Walter E. Washington Convention Center
    Abstract Time: 06:18 PM - 06:30 PM

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Glenn, Dorey A., University of North Carolina, Chapel Hill, North Carolina, United States
  • Henderson, Candace Dione, UNC Kidney Center, Chapel Hill, North Carolina, United States
  • Hu, Yichun, UNC Kidney Center & Divisions of Nephrology & Hypertension, Chapel Hill, North Carolina, United States
  • O'Shaughnessy, Michelle M., Stanford University, Palo Alto, California, United States
  • Greenbaum, Larry A., Emory University, Atlanta, Georgia, United States
  • Zee, Jarcy, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
  • Bomback, Andrew S., Columbia University, New York, New York, United States
  • Mariani, Laura H., University of Michigan, Ann Arbor, Michigan, United States
  • Gibson, Keisha L., UNC Kidney Center, Chapel Hill, North Carolina, United States
  • Hogan, Susan L., University of North Carolina, Chapel Hill, North Carolina, United States
  • Falk, Ronald J., UNC Kidney Center, Chapel Hill, North Carolina, United States
  • Mottl, Amy K., University of North Carolina, Chapel Hill, North Carolina, United States

Group or Team Name

  • CureGN Consortium
Background

Infections are an important contributor to patient morbidity and mortality in glomerular disease (GD). We sought to understand risk factors for infection among patients in the Cure Glomerulonephropathy (CureGN) study.

Methods

CureGN is a prospective multi-center cohort study of patients with biopsy-proven minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), or IgA nephropathy/vasculitis (IgAN/IgAV). Risk factors for time to first infection-related hospitalization or ED visit were identified using Cox proportional hazards regression. Cox models were adjusted for patient characteristics at enrollment, including demographics [age, race, sex], immunosuppression exposure, GD subtype, number of comorbid conditions, smoking status, time from initial biopsy, and laboratory measurements [eGFR, urine protein to creatinine ratio (UPC), and serum albumin].

Results

Of 1917 participants (43% female, 42% less than 20 years, 67% white), 165 subjects (9%) experienced a first infection over a median follow-up of 15.5 (IQR 7.5 – 24.9) months. In adjusted multivariate models, age < 10 or 20-59 (versus >60) years, black race, and a higher number of comorbidities were significantly (p<0.05) associated with an increased hazard for infection (Table). An association with corticosteroid exposure was of borderline significance (p=0.06).

Conclusion

Among CureGN participants, younger age, black race, and more comorbidities were independently associated with time to first infection-related hospitalization or ED visit. These findings might inform the development of strategies aimed at preventing infection in patients with GD.

Funding

  • NIDDK Support